Duopharma Manufacturing (Bangi)


Duopharma Marketing
Concise Prescribing Info
Acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, complicated skin & skin structure infections & intra-abdominal infections including polymicrobial eg, abscesses. Combination therapy for mild to moderately severe inflammatory pelvic disease.
Dosage/Direction for Use
Adult Acute exacerbation of chronic bronchitis 1 tab once daily for 5 days. Community-acquired pneumonia 1 tab once daily for 10 days. Acute bacterial sinusitis 1 tab once daily for 7 days. Mild to moderate pelvic inflammatory disease 1 tab once daily for 14 days. Complicated skin & skin structure infections IV therapy followed by 1 tab once daily for 7-21 days. Complicated intra-abdominal infection IV therapy followed by 1 tab once daily for 5-14 days.
May be taken with or without food.
Hypersensitivity to moxifloxacin or other quinolones. History of quinolone-related tendon disease/disorder. Congenital or documented acquired QT prolongation, electrolyte disturbances particularly in uncorrected hypokalaemia, clinically relevant bradycardia & heart failure w/ reduced left ventricular ejection fraction, previous history of symptomatic arrhythmias. Not to be used concurrently w/ QT interval-prolonging drugs. Hepatic impairment (Child-Pugh C), increased transaminase >5-fold ULN. Pregnancy & lactation. Patients <18 yr.
Special Precautions
Hypersensitivity. Discontinue use if antibiotic-associated diarrhea & colitis; 1st sign of pain or inflammation occurs. Not recommended for patients w/ complicated pelvic inflammatory disease; MRSA infections. Patients w/ ongoing proarrhythmic conditions eg, acute myocardial ischaemia or QT prolongation; bullous skin reactions eg, SJS or TEN; CNS disorders, risk factors predisposing to seizures or lowering seizure threshold; sensory or sensorimotor polyneuropathy; psychosis or history of psychiatric disease; G6PD deficiency. Avoid use in patients w/ known history of myasthenia gravis. Monitor blood glucose in diabetic patients. Vision disorders. Maintain adequate fluid intake. Concomitant use w/ oral hypoglycemic agent or insulin. Avoid exposure to UV irradiation or strong sunlight. Interference w/ Mycobacterium spp culture test. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive or use machines. Fulminant hepatitis potentially leading to hepatic failure. Renal impairment. Elderly.
Adverse Reactions
Superinfections; headache, dizziness; QT prolongation in patients w/ hypokalaemia; nausea, vomiting, GI & abdominal pain, diarrhoea; increased transaminases.
Drug Interactions
Increased risk of ventricular arrhythmias including Torsade de pointes w/ class IA & III antiarrhythmics, antipsychotics, TCAs, certain antimicrobials & antihistamines, cisapride, vincamine IV, bepridil, diphemanil. Impaired absorption w/ antacids, minerals, multivit, antiretroviral drugs eg, didanosine, Mg-, Al-, Fe- or Zn-containing prep, sucralfate. Increased anticoagulant activity. Reduced systemic availability w/ charcoal. Caution w/ loop & thiazide diuretics, high-dose laxatives & enemas, corticosteroids, amphotericin B.
MIMS Class
ATC Classification
J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Flonoxin FC tab 400 mg
1 × 5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in